CN116478265B - 一种衍生自猪肝脏抗菌肽tjh及其制备方法和应用 - Google Patents
一种衍生自猪肝脏抗菌肽tjh及其制备方法和应用 Download PDFInfo
- Publication number
- CN116478265B CN116478265B CN202211532077.4A CN202211532077A CN116478265B CN 116478265 B CN116478265 B CN 116478265B CN 202211532077 A CN202211532077 A CN 202211532077A CN 116478265 B CN116478265 B CN 116478265B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- tjh
- antibacterial peptide
- net positive
- positive charge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 51
- 210000004185 liver Anatomy 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims description 7
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 35
- 229920001184 polypeptide Polymers 0.000 claims abstract description 33
- 150000001413 amino acids Chemical class 0.000 claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 11
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 8
- 102100022685 Liver-expressed antimicrobial peptide 2 Human genes 0.000 claims abstract description 7
- 101710167888 Liver-expressed antimicrobial peptide 2 Proteins 0.000 claims abstract description 7
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 7
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 7
- 230000002949 hemolytic effect Effects 0.000 claims abstract description 7
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 4
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 238000001819 mass spectrum Methods 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000004007 reversed phase HPLC Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 5
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 244000144972 livestock Species 0.000 abstract description 5
- 241000192125 Firmicutes Species 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 230000000397 acetylating effect Effects 0.000 abstract 1
- 230000002862 amidating effect Effects 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108010036176 Melitten Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供一种衍生自猪肝脏的抗菌肽TJH及其制备方法和应用,属于农业畜牧兽医应用领域,其氨基酸序列如SEQ ID No.1所示。通过截取猪肝脏抗菌肽LEAP‑2氨基末端的23个氨基酸,得到一条多肽;将带负电氨基酸Asp和Glu均替换为疏水性氨基酸Leu,使其净正电荷含量为6、疏水值为0.519,最后,将C端酰胺化,N端乙酰化,进一步提高净正电荷和稳定性,得到净正电荷含量为7、疏水性为0.519的第二条多肽,命名为抗菌肽TJH。本发明的抗菌肽TJH对革兰氏阳性菌和革兰氏阴性菌都具有高效的杀菌作用,而且具有较低的溶血活性和真核细胞毒性,使其具备成为抗生素替代物的发展潜力。
Description
技术领域
本发明属于农业畜牧兽医应用领域,具体涉及一种衍生自猪肝脏抗菌肽TJH及其制备方法和应用。
背景技术
畜禽饲料中添加饲用抗生素能够提高动物肠道对营养物质的吸收和利用、改善肠道菌群丰富度、提高动物对病原微生物的免疫力。因此,抗生素作为饲料添加剂被广泛应用到畜禽养殖中。然而,随着全球耐药菌感染病例的持续上升,新一代抗菌药物的研发已迫在眉睫。抗菌肽是一种天然的小分子多肽,具有来源广泛和安全性高等特点,广泛存在于动植物和微生物体内,并因其独特的细胞膜作用机制而不易产生耐药性。抗菌肽不仅具有抗菌活性,而且对病毒、寄生虫、肿瘤等均有杀伤作用。因此,抗菌肽已成为生物领域的研究热点,尤其在畜牧兽医领域具有极为广阔的市场应用前景。故研究一种安全、高效的抗菌肽来代替饲用抗生素已经迫在眉睫。现有的猪肝脏表达的抗菌肽LEAP-2,其肽链长度较长,杀菌活性较差,不利于作为抗菌药物使用。
发明内容
基于以上问题,本发明的目的在于公开一种衍生自猪肝脏抗菌肽TJH,将具有77个氨基酸长度的衍生自猪肝脏抗菌肽LEAP-2通过截取和替代的方法简化,并保留其活性中心,增加抗菌肽的杀菌活性,使其具备成为抗生素替代物的潜力。
本发明的目的是这样实现的:一种衍生自猪肝脏抗菌肽TJH,其氨基酸序列如SEQID No.1所示,其C端乙酰化,N端酰胺化。
本发明的另一目的是提供如上所述的一种衍生自猪肝脏抗菌肽TJH的制备方法,如下:通过截取猪肝脏抗菌肽LEAP-2氨基末端的23个氨基酸,得到含有2个净正电荷、疏水值为0.100的一条多肽,其氨基酸序列为:RDDSECLTRLCRKRRCSLSVAQE;然后将该条多肽的带负电氨基酸Asp和Glu均替换为疏水性氨基酸Leu,以提高疏水性和净正电荷,得到第二条多肽,其氨基酸序列如SEQ ID No.1所示,其净正电荷含量为6、疏水值为0.519,最后,将所述的第二条多肽的C端酰胺化,N端乙酰化,进一步提高净正电荷和稳定性,其净正电荷含量为7、疏水性为0.519,然后采用固相化学合成法和反相高效液相色谱纯化和质谱鉴定后,即完成第二条多肽的制备;再经过杀菌活性的测定、溶血活性的测定、真核细胞毒性的测定,最终将第二条多肽命名为抗菌肽TJH。
本发明的另一目的是提供如上所述的一种衍生自猪肝脏表达抗菌肽TJH在制备治疗革兰氏阴性菌和/或革兰氏阳性菌感染性的疾病的药物中的应用。
进一步的,如上所述的应用,所述的革兰氏阴性菌为大肠杆菌。
进一步的,如上所述的应用,所述的革兰氏阳性菌为金黄色葡萄球菌。
本发明的有益效果及优点如下:本发明对抗菌肽TJH进行生物学活性检测,发现其不但对大肠杆菌、金黄色葡萄球菌等6种菌种有高效的杀灭作用,而且具有较低的溶血活性和真核细胞毒性,该抗菌肽在128μM浓度下造成1.25%的红细胞溶血,未能引起10%的红细胞溶血,在64μM浓度下小鼠巨噬细胞RAW264.7的存活率达到了90.83%,其已具备成为饲用抗生素替代物的发展潜力。
附图说明
图1为本发明的抗菌肽TJH的高效液相色谱图。
图2为本发明的抗菌肽TJH的基质辅助激光解吸/电离飞行时间质谱图。
图3为本发明的抗菌肽TJH的杀菌活性图。
图4为本发明的抗菌肽TJH和蜂毒素ME的溶血活性图。
图5为本发明的抗菌肽TJH和蜂毒素ME的细胞毒性图。
具体实施方式
下面根据说明书附图举例对本发明做进一步的说明:
实施例1
抗菌肽的设计
猪肝脏表达抗菌肽LEAP-2的氨基酸序列为:
MWHLKLFAVLVICLLLAVQVHGSPIPELSSAKRRPRRMTPFWRAVSLRPIGASCRDDSECLTRLCRKRRCSLSVAQE;
通过截取猪肝脏抗菌肽LEAP-2的氨基末端的23个氨基酸,得到含有2个净正电荷,疏水值为0.100的抗菌肽。
获得的一条多肽,其氨基酸序列为:
RDDSECLTRLCRKRRCSLSVAQE
将带负电氨基酸Asp和Glu替换为疏水性氨基酸Leu以提高疏水性和净正电荷,得到第二条多肽,其净正电荷含量为6个,疏水值为0.519,其氨基酸序列为:
RLLSLCLTRLCRKRRCSLSVAQL
最后,将第二条多肽的N端酰胺化,C端乙酰化以进一步提高净正电荷和稳定性,得到净电荷含量为7,疏水性为0.519的抗菌肽TJH。抗菌肽TJH的序列如表1所示。
表1抗菌肽TJH的氨基酸序列。
实施例2:
固相化学合成法合成抗菌肽
1、抗菌肽的制备从C端到N端逐一进行,通过多肽合成仪来完成。首先将Fmoc-X(X是每个抗菌肽的C端第一个氨基酸)接入到Wang树脂,然后脱去Fmoc基团后得到X-Wang树脂;再将Fmoc-Y-Trt-OH(9-芴甲氧羧基-三甲基-Y,Y为每个抗菌肽C端第二个氨基酸);按照这个程序依次从C端合成到N端,直至合成完毕,得到脱去Fmoc基团的侧链保护的树脂;
2、在上述得到的肽树脂中,加入切割试剂,20℃避光下反应2h,过滤;沉淀TFA(三氟乙酸)洗涤,将洗液与上述滤液混合,旋转蒸发仪浓缩,再加入10倍左右体积的预冷无水乙醚,-20℃沉淀3h,析出白色粉末物,以2500g离心10min,收集沉淀,再用无水乙醚洗涤沉淀,真空干燥,得到多肽,其中切割试剂由TFA、水和TIS(三异丙基氯硅烷)按照质量比95:2.5:2.5混合而成;
3、使用0.2M的硫酸钠(磷酸调节至pH7.5)进行柱平衡30min,用90%乙腈水溶液溶解多肽,过滤,C18反相常压柱,采用梯度洗脱(洗脱剂为甲醇和硫酸钠水溶液按照体积比为30:70~70:30混合),流速为1mL/min,检测波为220nm,收集主峰,冻干;再利用反相C18柱进一步纯化,洗脱液A为0.1%TFA/水溶液;洗脱液B为0.1%TFA/乙腈溶液,洗脱浓度为25%B~40%B,洗脱时间为12min,流速为1mL/min,再同上收集主峰,冻干;
4、抗菌肽的鉴定:将上述得到的抗菌肽经过电喷雾质谱法分析,质谱图中显示的分子量(如图1、2所示)与表1中的理论分子量基本一致,抗菌肽的纯度大于95%。
实施例3
1、杀菌活性的测定:以PBS为稀释液,将12.5μl的浓度为16μM的抗菌肽加入到987.5μl的PBS中,取上述溶液100μl置于1.5ml EP管内,然后添加等体积的待测菌液,孵育2h。随后,取10μl孵育完成的菌液加入990μl的PBS,震荡后取10μl稀释液均匀涂布在固体培养基MHA上。阳性对照组为未经过抗菌肽处理的细菌样品。37℃恒温培养12-18h,计算细菌存活率。通过图3可以看出,TJH对革兰氏阴性菌(E.coli 25922、E.coli UB1005和E.coliK99)和革兰氏阳性菌(S.aureus 29213、S.aureus 12228和S.aureus 43300)均表现出较高的杀菌活性。
2、溶血活性的测定:采集人的新鲜血液1mL,肝素抗凝后溶解到2mL PBS溶液中,3000rpm离心10min,收集红细胞;用PBS洗涤3遍,再用10mL PBS重悬;取50μL红细胞悬液与50μL用PBS溶解的不同浓度的抗菌肽溶液混合均匀,在37℃培养箱内恒温孵育1h;孵育结束后取出,4℃、3000rpm下离心10min;取出上清液用酶标仪在570nm处测光吸收值。其中50μL红细胞加50μL PBS作为阴性对照;50μL红细胞加50μL0.1%Tritonx-100作为阳性对照。最小溶血浓度是抗菌肽引起10%溶血率时的抗菌肽浓度,检测结果见图4。通过图4可以看出,抗菌肽TJH在检测范围内未表现出溶血活性,该抗菌肽在128μM浓度下造成1.25%的红细胞溶血,未能引起10%的红细胞溶血,与对照组蜂毒素ME呈显著性差异。
3、真核细胞毒性的测定:采用MTT法检测小鼠巨噬细胞RAW264.7的细胞毒性。
(1)培养基的准备及细胞的培养:将DMEM(培养基)与胎牛血清按9:1混合配置完全培养基,并复苏液氮中的小鼠巨噬细胞RAW264.7,以细胞长满瓶底80%-90%为宜。
(2)待测细胞的处理:无菌PBS清洗并重悬细胞3次,并用0.25%胰蛋白酶溶液对细胞消化处理,使其在瓶底脱落,用完全培养基冲洗,获得单个细胞悬液,同时在96孔板中填入终浓度约为2×104的50μL细胞悬液。
(3)抗菌肽处理:96孔板第一孔内加入10μL抗菌肽并倍比稀释,96孔板1-10孔内加入50μL稀释后的细胞悬液,第11孔加50μL完全培养基,第12孔加100μL完全培养基。恒温培养4h;
(4)毒性检测:取50μL 5mg/mL MTT溶液加入96孔板,继续培养3-4h后,加入150μLDMSO,酶标仪OD570nm处测定吸光度,检测结果见图5。通过图5可以看出,抗菌肽TJH在检测范围内未表现出对小鼠巨噬细胞RAW264.7的毒性,与对照组蜂毒素ME呈现显著性差异。
Claims (3)
1.一种衍生自猪肝脏抗菌肽TJH,其特征在于,其氨基酸序列如SEQ ID No.1所示,其C端酰胺化,N端乙酰化。
2.根据权利要求1所述的一种衍生自猪肝脏抗菌肽TJH的制备方法,其特征在于,方法如下:通过截取猪肝脏抗菌肽LEAP-2氨基末端的23个氨基酸,得到含有2个净正电荷、疏水值为0.100的一条多肽,其氨基酸序列为:RDDSECLTRLCRKRRCSLSVAQE;然后将该条多肽的带负电氨基酸Asp和Glu均替换为疏水性氨基酸Leu,以提高疏水性和净正电荷,得到第二条多肽,其氨基酸序列如SEQ ID No.1所示,其净正电荷含量为6、疏水值为0.519,最后,将所述的第二条多肽的C端酰胺化,N端乙酰化,进一步提高净正电荷和稳定性,其净正电荷含量为7、疏水性为0.519,然后采用固相化学合成法和反相高效液相色谱纯化和质谱鉴定后,即完成第二条多肽的制备;再经过杀菌活性的测定、溶血活性的测定、真核细胞毒性的测定,最终将第二条多肽命名为抗菌肽TJH。
3.根据权利要求1所述的一种衍生自猪肝脏抗菌肽TJH在制备治疗大肠杆菌和/或金黄色葡萄球菌感染性的疾病的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211532077.4A CN116478265B (zh) | 2022-12-01 | 2022-12-01 | 一种衍生自猪肝脏抗菌肽tjh及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211532077.4A CN116478265B (zh) | 2022-12-01 | 2022-12-01 | 一种衍生自猪肝脏抗菌肽tjh及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116478265A CN116478265A (zh) | 2023-07-25 |
CN116478265B true CN116478265B (zh) | 2023-10-27 |
Family
ID=87216619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211532077.4A Active CN116478265B (zh) | 2022-12-01 | 2022-12-01 | 一种衍生自猪肝脏抗菌肽tjh及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116478265B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111518168A (zh) * | 2020-03-30 | 2020-08-11 | 东北农业大学 | 一种衍生自肉食杆菌素的抗菌肽及其制备方法和应用 |
-
2022
- 2022-12-01 CN CN202211532077.4A patent/CN116478265B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111518168A (zh) * | 2020-03-30 | 2020-08-11 | 东北农业大学 | 一种衍生自肉食杆菌素的抗菌肽及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN116478265A (zh) | 2023-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108570103B (zh) | 一种富含色氨酸抗菌肽wk12及其制备方法和应用 | |
CN111533786B (zh) | 色氨酸和精氨酸跨链交互作用的β发卡抗菌肽及制备方法 | |
CN111423501B (zh) | 一种衍生自蝎毒的抗菌肽及制备方法和应用 | |
CN109232717B (zh) | 一种针对革兰氏阴性菌靶向抗菌肽及制作方法与应用 | |
CN111518168B (zh) | 一种衍生自肉食杆菌素的抗菌肽及其制备方法和应用 | |
CN107746429A (zh) | 一种末端对称抗菌肽pp及其制备方法和应用 | |
CN111533789B (zh) | 色氨酸和赖氨酸跨链交互作用的β发卡抗菌肽及制备方法 | |
CN115960261A (zh) | 色氨酸和苯丙氨酸跨链交互β-发卡抗菌肽WFL及其制备方法和应用 | |
CN107266533A (zh) | 一种α螺旋抗菌肽RL及其制备方法和应用 | |
CN113549137B (zh) | 一种靶向革兰氏阴性菌的富脯氨酸抗菌肽Pyr-2及其制备方法与应用 | |
CN116693621B (zh) | 抑制革兰氏阴性菌的窄谱抗菌肽pc及其制备方法和应用 | |
CN111533787B (zh) | 一种线性抗菌肽及其制备方法和应用 | |
CN111533781B (zh) | 非特异受体结合型真菌靶向抗菌肽及其制备方法和应用 | |
CN116375877B (zh) | 一种细胞穿透抗菌肽pw2及其制备方法和应用 | |
CN111647044A (zh) | 一种富含苯丙氨酸抗菌肽及其制备方法和应用 | |
CN113214355A (zh) | 一种专杀真菌的抗菌肽gl4w及其制备方法和应用 | |
CN109705195B (zh) | 一种大肠杆菌靶向抗菌肽ki-qk及制备方法和应用 | |
CN116478265B (zh) | 一种衍生自猪肝脏抗菌肽tjh及其制备方法和应用 | |
CN116041476B (zh) | 一种衍生自猪肝脏表达抗菌肽malk及其制备方法和应用 | |
CN113956340B (zh) | 一种衍生自羊源抗菌肽rlr及其制备方法和应用 | |
CN116284250B (zh) | 耐蛋白酶水解的高稳定抗菌肽hw及其制备方法和应用 | |
CN110437305B (zh) | 一种尾端锚定的α螺旋抗菌肽GW4A及制备方法和应用 | |
CN106589076A (zh) | 一种中心对称的α螺旋肽及制备方法和应用 | |
CN106518999B (zh) | 基于微缩肽策略的抗菌肽ww及其制备方法和应用 | |
CN115925990B (zh) | 一种衍生自猪导管素的抗菌肽及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |